Loading clinical trials...
Loading clinical trials...
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Conditions
Interventions
PLX3397
sirolimus
Locations
5
United States
University of Iowa
Iowa City, Iowa, United States
Early Drug Development Center
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Washington University in St. Louis
St Louis, Missouri, United States
Columbia University
New York, New York, United States
Start Date
November 4, 2015
Primary Completion Date
July 1, 2023
Completion Date
October 1, 2024
Last Updated
March 21, 2025
NCT07548177
NCT07467772
NCT05969860
NCT04308330
NCT04693377
NCT07308886
Lead Sponsor
Gulam Manji
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions